Market cap
$322.9m
End-of-day close multiplied by current shares on issue.
PEB · NZX
Pacific Edge (PEB)
Healthcare / DiagnosticsCovered: FY24 - HY264 published briefings
Pacific Edge is an NZX-listed healthcare / diagnostics company with FY24 - HY26 of published result briefings.
Sections
Snapshot
Latest metrics
HY26, released 25 November 2025
← Swipe to view more
| Metric | Value | Change |
|---|---|---|
| Revenue | $5.9m | ↓ -45.8% |
| NPAT | -$19.1m | ↓ -31.7% |
| Operating cash flow | -$19m | ↓ -52.5% |
| Net debt | -$14.8m | ↑ +31.5% |
| ROE % | -71.0% | ↓ -35.3pp |
| PBT | -$19.1m | ↓ -31.7% |
| Inventory days | 119 | ↑ +167.0% |
| Total assets | $34.7m | ↓ -31.8% |
Source: latest published briefing (HY26, released 25 November 2025). Change compares against the prior equivalent period: HY25, released 26 November 2024.
Valuation
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
Prices as at close, 27 July 2026
Price and market cap
The latest close and share count context for the market price.
i
Profitability multiples
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.03
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
Not available
Not available for this company right now.
P/B
12x
Market value compared with latest reported equity.
Income and fund shape
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Price history
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Share price
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Loading chart...
Chat
Ask about PEB
Ask follow-up questions about Pacific Edge's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Ask about PEB
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
Performance over time
The latest period is shown first.
← Swipe to view more
| Metric | HY266 MONTHS25 November 2025 | FY2512 MONTHS30 May 2025 | HY256 MONTHS26 November 2024 | FY2412 MONTHS21 May 2024 | Trend |
|---|---|---|---|---|---|
| Revenue | $5.9m | $21.8m | $11m | $23.9m | Chart |
| Revenue growth % | -45.8% | -8.6% | -16.3% | 21.9% | Chart |
| PBT | -$19.1m | -$29.9m | -$14.5m | -$29.5m | Chart |
| NPAT | -$19.1m | -$29.9m | -$14.5m | -$29.5m | Chart |
| Operating cash flow | -$19m | -$24.7m | -$12.5m | -$25.8m | Chart |
| FCF pre-lease | — | -$26m | -$13m | -$27.1m | Chart |
| ROE % | -71.0% | n/m | -35.7% | -43.0% | Chart |
| Net debt | -$14.8m | -$9.2m | -$21.6m | -$29m | Chart |
| Debtor days | — | 47 | — | 39 | Chart |
| Inventory days | 119 | 27 | 45 | 26 | Chart |
| Total assets | $34.7m | $37m | $50.9m | $65.4m | Chart |
Reference: annolyse.ai/companies/peb
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
Filing-only history charts
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Revenue
Reported revenue across covered periods.
Loading chart...
Revenue growth
Like-period revenue growth where comparable.
Loading chart...
NPAT
Statutory profit after tax.
Loading chart...
Operating cash flow
Cash generated from operations.
Loading chart...
FCF pre-lease
Operating cash flow less capex before leases.
Loading chart...
ROE
Return on equity.
Loading chart...
Full chartable metric set
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Net debt
Borrowings less cash; negative values indicate net cash.
Loading chart...
Debtor days
Receivables days where the working-capital inputs are source-backed.
Loading chart...
Inventory days
Inventory days where the working-capital inputs are source-backed.
Loading chart...
The setup & the reality
FY25 → HY26 Follow-through
The latest result is checked against what the prior briefing said to watch.
Historical setup
What FY25 said to watch
Previous analysisFY25Result releasedAnnolyse analysis published
From Cash falls 67.6% to NZ$9.5M as revenue drops 8.6% on Medicare uncertainty
No formal financial guidance has been provided, so there is no numeric target against which to assess FY25. Management's stated framing — a "holding pattern" awaiting Medicare resolution — implies that FY25 results are not intended to represent a normalised run rate. The APAC contribution and sales force efficiency gains are cited as partial offsets, and US Tests/Sales FTE improved 6.4% in Q4 FY25 versus Q4 FY24, suggesting some operational recovery in the final quarter.
However, the absence of a clear Medicare resolution timeline means the path to cash-flow neutrality is undefined. The second-half revenue of NZ$10.9M being marginally below the first-half NZ$11.0M does not support a "sequential improvement" narrative, and the closing cash position means the company will need either a step-change in revenue or an external capital event in the near term.
Open questions
Open questions from FY25
- What is the specific timeline and probability of a Medicare coverage decision, and what revenue uplift does management model under a favourable outcome?
- How does the board plan to fund operations beyond the near-term implied by the NZ$9.5M cash balance — is a capital raise, partnering transaction, or cost-reduction program under active consideration?
- Why did receivable days extend to 47.2 days in a period when volume fell, and are there collection issues with specific payers or geographies?
- What drove the NZ$15.0M Research segment loss, and is the NZ$4.8M in Research revenue contractually recurring or episodic?
- Will the US sales force be rebuilt once Medicare uncertainty resolves, and what is the cost and time to restore peak sales coverage?
This briefing cannot assess whether Pacific Edge's cash position is sufficient to reach a Medicare decision, nor can it evaluate the probability or timing of that regulatory outcome.
Archive
Briefing archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
HY26 · Released 25 November 2025
Revenue down 45.8% as Medicare coverage loss halves US diagnostic income
Pacific Edge's HY26 operating loss widened to NZ$19.1M after Medicare coverage was withdrawn, with just NZ$15.1M cash remaining to fund an ongoing
Read briefing
FY25 · Released 30 May 2025
Cash falls 67.6% to NZ$9.5M as revenue drops 8.6% on Medicare uncertainty
Pacific Edge burned NZ$24.7M in operating cash in FY25, leaving a closing balance of NZ$9.5M that raises immediate questions about runway without a
Read briefing
HY25 · Released 26 November 2024
Revenue fell 16.3% with under a year of cash at current burn rate
Loss narrowed just 4.9% despite a smaller cost base, leaving $21.9m of cash against a $12.5m half-year operating burn.
Read briefing
FY24 · Released 21 May 2024
Revenue rose 21.9% but losses widened 9.5% with cash down to $29.3m
Cash burn held near $25.8m while equity eroded 34% to $54.6m, leaving runway as the central question on a still loss-making business.
Read briefing
Get notified when PEB publishes
Get the next Pacific Edge result briefing and five-year history updates by email.